Bipartisan Senators Introduce Bill to Stop Federal Hemp THC Ban and Replace It With FDA Regulations

Bipartisan Senators Introduce Bill to Stop Federal Hemp THC Ban

A bipartisan pair of U.S. senators has introduced legislation that could prevent a sweeping federal ban on hemp-derived THC products while establishing nationwide safety standards for the rapidly growing cannabinoid industry. Republican Senator Tim Sheehy of Montana and Democratic Senator Amy Klobuchar of Minnesota unveiled the Hemp Guardrails Act on November 17, 2026, proposing a comprehensive regulatory framework that would allow qualifying hemp products to remain federally legal under the supervision of the Food and Drug Administration. The legislation arrives just weeks before a December 11 deadline that threatens to eliminate much of the existing hemp-derived THC marketplace.

The proposal would replace broad restrictions on hemp cannabinoids with enforceable rules governing manufacturing, laboratory testing, packaging, labeling, marketing, and retail distribution. It would prohibit sales to individuals younger than 21, restrict several intoxicating cannabinoids, establish new standards for hemp cultivation, and create a legal pathway for qualifying CBD products. The legislation also seeks to protect American farmers and manufacturers by requiring covered products distributed through interstate commerce to originate from hemp cultivated and processed domestically.

The Hemp Guardrails Act represents a significant attempt to resolve one of the most contentious cannabis policy disputes in Congress. Supporters argue that the government can protect children and consumers without destroying legitimate businesses that developed following hemp legalization in 2018. Critics of the existing hemp marketplace maintain that insufficient oversight has allowed intoxicating products to be sold without adequate safeguards. By combining stricter federal enforcement with continued legal access to qualifying products, the new legislation attempts to address both concerns before the December deadline takes effect.

Senators Tim Sheehy and Amy Klobuchar Introduce the Hemp Guardrails Act

The Hemp Guardrails Act was formally introduced November 17 by Sheehy and Klobuchar, representing an unusual bipartisan agreement on a controversial cannabis-related issue. Both senators have emphasized the importance of protecting consumers while preserving legitimate hemp businesses, particularly farmers and manufacturers facing uncertainty about the future of their products. Sheehy has argued that federal policy should distinguish responsible businesses from operators selling unsafe or improperly marketed cannabinoids. Klobuchar has similarly emphasized the economic importance of Minnesota’s hemp industry and the need for a regulatory approach that protects children without eliminating products used by adult consumers.

The senators’ proposal would amend the Agricultural Marketing Act of 1946 and the Federal Food, Drug, and Cosmetic Act, creating new definitions and regulatory responsibilities specifically for hemp-derived cannabinoid products. Rather than treating all intoxicating hemp products as categorically prohibited, the legislation distinguishes among naturally occurring cannabinoids, chemically manufactured substances, pharmaceutical products, and different consumer formulations. Its central objective is to establish a consistent national system capable of addressing product safety while allowing eligible businesses to continue operating. However, the measure remains proposed legislation and does not currently change the federal restrictions scheduled for December.

Federal Hemp THC Restrictions Threaten a Multibillion-Dollar Industry

The controversy began with the Agriculture Improvement Act of 2018, commonly known as the Farm Bill, which removed qualifying hemp from the federal Controlled Substances Act. Hemp was defined primarily according to its delta-9 THC concentration, with plants and derivatives containing no more than 0.3% delta-9 THC by dry weight generally excluded from federal marijuana restrictions. The legislation encouraged agricultural hemp cultivation but also created opportunities for manufacturers to develop cannabinoid beverages, gummies, oils, and other consumer products. Over time, a substantial commercial market emerged around hemp-derived THC and related compounds, including products capable of producing intoxicating effects.

In November 2025, Congress approved legislation narrowing the federal hemp definition, including a restriction limiting finished products to 0.4 milligrams of total THC and other similarly acting cannabinoids per container. The new framework threatened many existing products, including THC-infused beverages and some full-spectrum CBD preparations. Although the restrictions were initially scheduled for November 12, 2026, Congress subsequently delayed most provisions until December 11. A separate restriction covering cannabinoids that cannot naturally be produced by the cannabis plant took effect November 12. The Hemp Guardrails Act would create an alternative to the broader December restrictions, but lawmakers must still approve the proposal before it can become law.

Hemp Cultivation THC Limit Would Increase to 1 Percent

One of the most significant provisions would raise the allowable THC concentration for hemp cultivation from 0.3% to 1% on a dry-weight basis. Unlike the original 2018 definition, which focused on delta-9 THC, the proposed threshold would measure total tetrahydrocannabinols, including THCA. This approach recognizes that different THC compounds can contribute to a product’s intoxicating potential while offering farmers greater flexibility when cultivating hemp varieties that naturally develop higher cannabinoid concentrations. Supporters argue that the current 0.3% threshold can cause agricultural losses when crops exceed the legal limit because of environmental conditions, plant genetics, or natural variations during cultivation.

The legislation also addresses hemp ingredients undergoing processing. Certain unfinished cannabinoid extracts, concentrates, and distillates could temporarily exceed the 1% total-THC threshold when handled by authorized manufacturers and intended for further production. These materials could not be sold directly to consumers or distributed outside permitted commercial channels. The exception recognizes that cannabinoid concentrations often change during extraction and refinement, even when the resulting consumer product ultimately satisfies applicable legal requirements. Importantly, a 1% agricultural threshold would not mean every finished hemp product could contain unrestricted amounts of THC. Consumer products would remain subject to the bill’s separate prohibitions, FDA regulations, and applicable state restrictions.

Delta-8, Delta-10 and THC-O Products Would Remain Prohibited

Although the proposal seeks to preserve a legal market for hemp-derived cannabinoids, it would impose substantial restrictions on products containing certain intoxicating compounds. The legislation identifies delta-8 THC, delta-10 THC, hexahydrocannabinol, commonly known as HHC, and THC-O acetate as restricted cannabinoids. Products containing more than trace amounts of these substances would generally be excluded from the protected hemp category. The restrictions also extend to related compounds and derivatives meeting the legislation’s definition. Supporters argue that these measures are necessary because some cannabinoids have entered commercial markets without sufficient toxicological research, manufacturing oversight, or reliable consumer safety information.

The bill distinguishes these restricted compounds from cannabinoids such as CBD, CBG, CBC, CBN, CBDV, THCV, and delta-9 THC. It would also permit certain manufacturing processes involving naturally occurring cannabinoids, subject to the resulting products meeting federal requirements. Another major provision would prohibit the introduction of raw hemp flower, smokable hemp flower, and pre-rolls intended for inhalation into interstate commerce as consumer products. Consequently, the legislation should not be interpreted as an attempt to preserve every product currently marketed as legal hemp. It would protect selected categories of cannabinoid products while significantly restricting others that lawmakers consider especially difficult to regulate safely.

FDA Would Establish National Hemp Product Safety Regulations

A central feature of the Hemp Guardrails Act involves expanding the FDA’s responsibilities over hemp-derived consumer products. The legislation would create a dedicated regulatory category under the Federal Food, Drug, and Cosmetic Act and direct federal health officials to establish implementing regulations within 180 days of enactment. These rules would cover manufacturing practices, laboratory testing, ingredient controls, packaging, product labeling, facility registration, recordkeeping, and procedures for removing unsafe merchandise from the market. Manufacturers would be expected to comply with standardized federal requirements rather than relying exclusively on the different regulatory systems currently used by individual states.

The proposal would require independent laboratory testing of finished products to evaluate cannabinoid concentrations, relevant components, and potential contaminants. Packaging would need to provide access to a certificate of analysis through a QR code, another scannable mechanism, or an internet address. The FDA would receive authority to inspect facilities, identify adulterated or misbranded products, and pursue enforcement actions when manufacturers fail to meet established standards. Product recalls and removal procedures would also become part of the regulatory framework. These requirements could improve accountability in an industry where inconsistent testing methods, inaccurate potency labels, and questionable manufacturing practices have generated recurring safety concerns.

Federal Minimum Age of 21 Would Protect Younger Consumers

The legislation would establish a nationwide minimum age of 21 for purchasing, possessing, or consuming covered hemp-derived cannabinoid products. This provision addresses a longstanding concern about the availability of intoxicating hemp merchandise through retail channels that have not always maintained the same age verification standards as licensed marijuana dispensaries. Under the proposal, businesses would be prohibited from selling qualifying cannabinoid products to minors, while federal regulators would establish additional safeguards intended to prevent accidental access and consumption. The restrictions would apply to covered products regardless of whether they were marketed primarily for recreational enjoyment or general wellness purposes.

Packaging and advertising would face additional scrutiny. The bill prohibits misleading product promotions, imitation branding, and packaging designed to resemble products commonly marketed to children. Required warnings would communicate relevant safety information, while child-resistant containers would reduce the likelihood of accidental ingestion. These measures respond to concerns about THC gummies and other products resembling ordinary candy or food. Although age restrictions and packaging requirements cannot eliminate every risk, supporters believe they would establish a more consistent foundation for consumer protection while allowing appropriately regulated adult sales to continue.

CBD Products Would Receive a Clearer Federal Regulatory Pathway

The Hemp Guardrails Act also addresses uncertainty surrounding cannabidiol, one of the most commercially significant non-intoxicating cannabinoids. CBD products have remained widely available since the 2018 Farm Bill, but their legal treatment under federal food and dietary supplement regulations has been complicated. The FDA has maintained that certain CBD products cannot be marketed as conventional dietary supplements under existing provisions because CBD is also the active ingredient in an approved prescription medication. This interpretation has created uncertainty for businesses selling CBD oils, capsules, gummies, and other preparations intended for general consumer use.

The proposed legislation would establish a specific category for qualifying hemp-derived cannabinoid dietary supplements, potentially providing a clearer pathway for lawful marketing under federal safety requirements. Products would still need to comply with applicable labeling, manufacturing, and consumer protection standards, and the legislation would not authorize unsupported claims that CBD treats or cures medical conditions. The proposal also preserves federal authority concerning certain Centers for Medicare & Medicaid Services initiatives involving hemp-derived cannabinoid supplements. These provisions could provide greater regulatory certainty for manufacturers and consumers, although the practical consequences would depend on future FDA implementation and the treatment of specific products.

American Hemp Farmers and Manufacturers Would Receive New Protections

The bill contains several provisions designed to support domestic hemp agriculture and manufacturing. Covered hemp-derived cannabinoid products entering interstate commerce would need to originate from hemp cultivated in the United States and undergo processing, finishing, packaging, and labeling domestically. This requirement is intended to discourage reliance on imported cannabinoid ingredients and products that may not meet consistent American manufacturing standards. It could also create opportunities for U.S. farmers, extraction facilities, testing laboratories, packaging companies, and manufacturers supplying the regulated hemp marketplace.

Industry supporters describe the economic stakes as substantial. Sheehy’s office estimates that America’s hemp industry represents approximately $30 billion in commercial activity and supports around 350,000 jobs, although estimates vary depending on which hemp sectors are included. A broad federal prohibition could affect businesses well beyond cannabinoid retailers, including agricultural suppliers, beverage manufacturers, transportation companies, and independent distributors. The proposed domestic production requirements may benefit American operators but could also require some companies to restructure sourcing agreements and manufacturing relationships. For smaller businesses, compliance costs associated with laboratory testing, facility registration, and product reformulation would remain significant even under a regulatory alternative to prohibition.

States Would Retain Authority to Enforce Stricter Hemp Regulations

Another important provision preserves the ability of states, territories, and tribal governments to establish hemp regulations more restrictive than federal requirements. This means passage of the Hemp Guardrails Act would not automatically require every state to permit the same products or establish identical retail markets. States could continue imposing stricter potency limits, manufacturing requirements, distribution rules, and other restrictions intended to address local public health concerns. The legislation therefore recognizes that hemp regulation has developed differently across the country and that individual jurisdictions may wish to maintain additional safeguards.

However, the proposal also addresses interstate transportation. States and tribal governments would generally be prohibited from blocking the passage and delivery of federally compliant hemp-derived cannabinoid products traveling through their jurisdictions. This distinction separates the authority to regulate local commercial sales from the movement of lawful goods between other destinations. Such provisions could become important for manufacturers transporting products through states that maintain restrictive hemp laws. Nevertheless, businesses would still need to evaluate the rules governing their intended retail markets rather than assuming federal compliance provides unrestricted authority to sell products everywhere.

Hemp Industry Welcomes Bipartisan Alternative to Prohibition

The proposal has received support from prominent hemp industry representatives who argue that federal regulation offers a more sustainable alternative to broad restrictions. The U.S. Hemp Roundtable welcomed the legislation as a framework capable of preserving legitimate businesses while removing unsafe products and irresponsible operators from the marketplace. Jonathan Miller, the organization’s general counsel, emphasized the importance of manufacturing standards, third-party testing, protections for minors, and continued access to non-intoxicating CBD products and qualifying low-dose hemp beverages. CBD manufacturer Charlotte’s Web also endorsed the legislation, highlighting its potential to establish consistent federal standards while maintaining consumer access.

Nevertheless, the proposal may face opposition from lawmakers and organizations that prefer stricter limits on intoxicating hemp products. Public health advocates have raised concerns about increasing cannabinoid potency, accidental childhood exposure, impaired driving, and inconsistent product quality. Some licensed marijuana businesses also argue that hemp-derived THC products should face comparable taxation, licensing, and oversight requirements to those imposed on state-regulated cannabis operators. The Hemp Guardrails Act attempts to address several of these concerns, but disagreements may continue over acceptable THC concentrations, which products should qualify for interstate commerce, and whether FDA oversight can provide adequate enforcement across a large national market.

Congress Faces December 11 Deadline to Prevent Broader Hemp Restrictions

The legislation arrives during a critical period for federal hemp policy. The December 11 deadline coincides with the expiration of temporary federal government funding, creating an opportunity for lawmakers to consider hemp provisions as part of a larger appropriations agreement. Some congressional leaders have suggested that attaching hemp reform to must-pass spending legislation may provide a more realistic path toward enactment than attempting to advance a standalone measure through the full legislative process. Additional proposals from both parties have called for delaying the restrictions, establishing age limits, creating product testing requirements, or regulating hemp-derived THC beverages through separate federal systems.

However, the Hemp Guardrails Act has not yet passed either chamber, and its introduction does not postpone the existing deadline. Even if lawmakers support the general concept of FDA regulation, they must still negotiate disagreements over product eligibility, enforcement, agricultural standards, and the scope of federal authority. The bill’s proposed effective date is December 11, 2026, but the FDA would receive up to 180 days after enactment to develop detailed implementing regulations. That creates a separate administrative challenge involving how compliant businesses would operate during the transition to the new system. Without congressional action, the previously enacted restrictions remain scheduled to take effect as planned.

What the Hemp Guardrails Act Means for the Future of Federal Cannabis Policy

The introduction of the Hemp Guardrails Act marks an important development in the national debate over hemp-derived cannabinoids. Instead of choosing between unrestricted commercial sales and broad federal prohibition, Senators Sheehy and Klobuchar are proposing a regulatory model that preserves selected products while establishing stronger requirements for consumer safety. The legislation combines a higher agricultural THC threshold, federal oversight, laboratory testing, age restrictions, domestic manufacturing requirements, and explicit prohibitions on certain cannabinoids. Its approach reflects growing recognition that the hemp industry has evolved into a diverse commercial sector requiring more detailed regulation than the original 2018 Farm Bill provided.

The outcome could influence the relationship between hemp, marijuana, and federal cannabis regulation for years to come. A successful legislative compromise could establish national rules for qualifying cannabinoid products without requiring comprehensive recreational marijuana legalization. Failure to reach an agreement would leave much of the industry facing the restrictive federal definition scheduled for December 11. For farmers, manufacturers, retailers, and consumers, the coming weeks will determine whether Congress adopts an alternative regulatory framework or allows the existing restrictions to reshape the hemp marketplace. The Hemp Guardrails Act provides a concrete bipartisan proposal, but its future depends on whether lawmakers can transform that agreement into binding federal law before the deadline arrives.

Leave a Reply

Your email address will not be published. Required fields are marked *